Biotech Values

[floblu14]

From the FDA Brief -

Even if Lovenox’s monthly U.S. sales revenue of $210 million were reduced by 60 percent due to competition with Sandoz’s generic product, the resultant loss of $378 million over the next three months comprises less than 1% of Sanofi’s total annual revenue – a significant figure to be sure, but not of sufficient magnitude to cause irreparable harm to a company the size of Sanofi, as courts in this Circuit have repeatedly held.

Among other reasons, this clearly states that SNY will be denied their injunction.